A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs SHR 1316 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 07 Jun 2017 Planned initiation date changed from 1 Jul 2017 to 19 Jun 2017.
- 04 May 2017 New trial record